Full Event Guide

Thank you to our speakers, sponsors, and delegates who joined us in September for the summit! If you are interested in the 2025 event, please get in touch at info@hansonwade.com

Browse the Full Event Guide to Discover:

1.

Explore the latest breakthroughs in muscarinics, digital therapeutics, non-hallucinogenic neuroplastogens and more

2.

Deep dive into the value of EEGs as translational tools in neuropsychiatry & beyond

3.

Navigate evolving regulatory hurdles in an era of growing potential for psychedelic drug approvals

4.

Pinpoint next-generation targets with minimal side effects using innovative symptom and circuit-based methodologies

5.

Advance the “gold standard” endpoint beyond subjective mood scales and strive for alignment with regulators on selected endpoints in trial design

NPD Full Event Guide

Having trouble downloading the brochure? Let us know here and we’ll email it to you instead

Browse the Event Guide for Exclusive Insights from the Likes Of:

Picture of Ariana Mullin, Neuropsychiatric Drug Development

Ariana Mullin

Director - Regulatory Affairs

Bristol Myers Squibb

Berra Yazar Klosinski, Neuropsychiatric Drug Development

Berra Yazar-Klosinski

Chief Scientific Officer

Lykos Therapeutics

Dan Smith, Neuropsychiatric Drug Development

Daniel Smith

Executive Director & Head of Translational Medicine

Alkermes

Guy Goodwin, Neuropsychiatric Drug Development

Guy Goodwin

CMO

COMPASS Pathways

Matt Harlin, Neuropsychiatric Drug Development

Matthew Harlin

Senior Director - Discovery Research & Early Phase , Translational Medicine

Otsuka